Marina França Dias

Marina França Dias

Auto-generated profile, based on publicly available information

Marina França Dias

Pharmaceutical Research and Development, Ezequiel Dias Foundation, Belo Horizonte, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2025 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
MDMarina F. Dias
Marina F. Dias
ECEstael Luzia Coelho Cruz-Cazarim
Estael Luzia Coelho Cruz-Cazarim
FPFrederico Pittella
Frederico Pittella
ABAna Baião
Ana Baião
APAna Catarina Pacheco
Ana Catarina Pacheco
SFSílvia Ligório Fialho
Sílvia Ligório Fialho

2 April 2025 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
CSCarolina Nunes Silva
Carolina Nunes Silva
LDLays Fernanda Nunes Dourado
Lays Fernanda Nunes Dourado
BABárbara Leão Agata
Bárbara Leão Agata
MFMaísa Angélica Silva Fernandes
Maísa Angélica Silva Fernandes
MDMarina França Dias
Marina França Dias
SFSílvia Ligório Fialho
Sílvia Ligório Fialho

9 October 2025 in Nanomedicine
Verified
Journal Article
Closed access
DADavi Trombini Aleixo
Davi Trombini Aleixo
ECEstael Luzia Coelho Cruz-Cazarim
Estael Luzia Coelho Cruz-Cazarim
KFKézia Cristine Barbosa Ferreira
Kézia Cristine Barbosa Ferreira
LGLívia N. Grossi
Lívia N. Grossi
WBWilson R. Braz
Wilson R. Braz
FPFrederico Pittella
Frederico Pittella
Although breast cancer treatments have improved, challenges like tumor heterogeneity and drug resistance remain. RNA interference (RNAi), especially through small interfering RNA (siRNA), is a promising strategy to silence specific genes and improve clinical outcomes. However, the clinical translation of siRNA has been limited by barriers related to stability, biodistribution, cellular uptake, among others. Nanoparticle-based delivery systems have emerged as transformative platforms to address these limitations, enhancing siRNA protection, targeting, and intracellular release. This review discusses the major breakthroughs in nanoparticle-mediated siRNA delivery for breast cancer treatment, focusing on how innovations in nanocarrier design have enhanced siRNA stability, targeting, and therapeutic efficacy. We highlight key characteristics in RNA interference mechanisms, the evolution of computational tools for optimizing siRNA design, and the approval of RNAi-based therapies that laid the foundation for oncologic applications. Special emphasis is given to the development of lipid, polymeric, and inorganic nanoparticles engineered for efficient siRNA delivery, their role in overcoming drug resistance when combined with conventional therapies, and the current progress of clinical trials against solid tumors. By integrating nanotechnology and RNAi, these breakthroughs offer new opportunities for precise, durable, and personalized strategies in breast cancer treatment, with the potential to transform the current therapeutic landscape.

13 February 2026 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
CSCarolina Silva
Carolina Silva
TIThomas Toshio Inoue
Thomas Toshio Inoue
MDMarina França Dias
Marina França Dias
SFSílvia Ligório Fialho
Sílvia Ligório Fialho
AJArmando da Silva Cunha Júnior
Armando da Silva Cunha Júnior
Chronic retinal disorders such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and noninfectious uveitis are among the leading causes of irreversible visual loss worldwide. Their management depends on repeated intravitreal injections of anti-VEGF agents or corticosteroids, which, despite proven efficacy, are associated with high treatment burden and cumulative risks. Sustained-release intravitreal drug delivery systems (DDSs) are effective strategies to prolong therapeutic activity, enhance bioavailability, minimize adverse events, and improve patient adherence. This review provides an overview of the evolution, clinical efficacy, and translational potential of intravitreal DDSs, from nonbiodegradable implants to biodegradable systems. Advances in polymeric design, hydrogels, in situ forming systems, and 3D-printed architecture, are discussed alongside emerging clinical candidates. Key formulation, preclinical, and regulatory barriers to clinical translation are also examined. Comprehensive search on PubMed, Scopus, Web of Science, ClinicalTrials.gov, and regulatory repositories was performed (data published up to December 2025). Intravitreal DDSs are redefining ocular pharmacotherapy by offering prolonged, localized drug release. However, further innovation in polymer design, bioerodible materials, and sterilization methods is essential to balance safety, efficacy, and manufacturability. Integration of precision medicine and next-generation biomaterials will be key to achieving fully optimized, minimally invasive retinal therapies.

21 October 2025 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
BCBrenda Fernanda Moreira Castro
Brenda Fernanda Moreira Castro
MLMargareth Lugin
Margareth Lugin
MGMaria Carolina Andrade Guerra
Maria Carolina Andrade Guerra
MDMarina França Dias
Marina França Dias
RLRebecca T. Lee
Rebecca T. Lee
SFSílvia Ligório Fialho
Sílvia Ligório Fialho

16 August 2026 in Experimental Eye Research
Verified
Journal Article
Open access
LDLays Fernanda Nunes Dourado
Lays Fernanda Nunes Dourado
CSCarolina Silva
Carolina Silva
CRCarolina Meireles Bastos Rodrigues
Carolina Meireles Bastos Rodrigues
ESEladio Flores Sanchez
Eladio Flores Sanchez
LOLuciana Oliveira
Luciana Oliveira
SFSílvia Ligório Fialho
Sílvia Ligório Fialho